Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Centre Francois Baclesse
Sponsor

Centre Francois Baclesse

France 3 Avenue Du General Harris, Cs 45026, 14076 Caen, France

About the sponsor

Clinical research includes advanced non-small cell lung cancer, with attention to tumours carrying EGFR mutations, ALK rearrangements, and ROS1 fusions after targeted treatment.

  • Platinum-based chemotherapy
  • Pemetrexed
  • Atezolizumab
  • Bevacizumab

The sponsor also funds research relevant to treatment selection in adenocarcinoma and biomarker-defined lung cancer populations.

About Specializations

Centre Francois Baclesse runs clinical trials in conditions such as Renal cell carcinoma, Thyroid cancer, Follicular thyroid cancer, Papillary thyroid cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Renal cell carcinoma

Recruiting

Study on Digital Monitoring of Symptoms in Patients with Advanced Kidney Cancer Treated with Cabozantinib and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Centre Francois Baclesse

Thyroid cancer+2

Recruiting

Study Comparing Two Treatment Strategies for Intermediate-Risk Thyroid Cancer Using Sodium Iodide (131I) in Patients with Post-Surgery Evaluation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium iodide (131I)
  • Sponsor:Centre Francois Baclesse

Gastric cancer

Not recruiting

Study of spartalizumab combined with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) for patients with resectable gastric cancer before and after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Centre Francois Baclesse

Non-small cell lung cancer recurrent

Not recruiting

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Francois Baclesse

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.